Unbiased Analysis of Today's Healthcare Issues

A biologic by any other name would smell as sweet?

How important is a name?  In the case of biologics and biosimilars, billions of dollars depends on whether biosimilars can share the same name as branded biologics.  WonkBlog explains the biologic vs. biosimilar debate: Biologics, which treat serious diseases like cancer and multiple sclerosis, are usually more expensive than conventional drugs, and they’re also harder to […]

Read the rest of this entry »

First biosimilar hits the market

Making a generic version of a single molecule drug is fairly straightforward.  Making a replica of a biologic treatment, however, is not.  Nevertheless, Congress signed into law the Biologics Price Competition and Innovation Act of 2009 (BPCI Act) to create a fast-track approval process for biological products that are demonstrated to be highly similar an FDA-approved biological product.  These products […]

Read the rest of this entry »

Quotation of the Day: Pricing of Biosimilars

Bilsimilars are biologic medical products whose active drug substance is made by a living organism or derived from a living organism by means of recombinant DNA or controlled gene expression methods. Biologic drugs can be patented, but once the patents expire, biosimilars can enter the market. Are biosimilars> priced similarly to generics? According to Ana […]

Read the rest of this entry »